Zimbabwe Introduces Two-Month HIV Prevention Injection

By Priviledge Zviregei

Zimbabwe has achieved a significant breakthrough in the fight against HIV with the introduction of a revolutionary HIV prevention injection that provides protection for two months. The injectable cabotegravir (CAB_LA) drug is now available as a pre-exposure prophylaxis (PrEP), marking a new era in HIV prevention and offering a potent and convenient means of reducing HIV transmission among high-risk individuals.

The New Start Centre in Harare proudly welcomed its first recipient of this life-changing treatment, representing a major advancement in public health in Zimbabwe.

CAB_LA has garnered attention for its convenience and efficacy, positioning it as a game-changer in the field of HIV prevention. Unlike the traditional daily pill regimen associated with PrEP, this injection is administered once every two months, offering a more practical and manageable option for those seeking protection against the virus.

Dr. Misheck Ruwende, a prominent figure in the medical community known for his advocacy on social media platforms, expressed his excitement about this breakthrough, stating on Twitter, “Good news! Zimbabwe had its first recipient of the HIV prevention injection today. A more convenient alternative to daily pills (PrEP). The injection is administered once every two months.”

While the HIV prevention injection is currently available free of charge, its accessibility remains limited. The specific criteria for selecting recipients of the injection have not been disclosed yet. Additionally, the injection is not yet available at public hospitals and can only be accessed through Population Solutions for Health at New Start Centres.

Efforts are underway to expand access to CAB_LA and educate the public about its benefits and usage. These campaigns aim to address any misconceptions or concerns surrounding the injection. Healthcare providers are being trained to administer the injection and provide comprehensive support to recipients.

Zimbabwe’s adoption of CAB_LA demonstrates the country’s unwavering commitment to combating HIV and improving public health outcomes. By pioneering the use of this innovative injection, Zimbabwe sets an example for other nations in the region, showcasing the potential of biomedical solutions in the ongoing battle against HIV.

This milestone achievement not only offers new hope for individuals at risk but also reinforces Zimbabwe’s position as a leader in public health innovation. As the country continues to embrace this groundbreaking approach to HIV prevention, the future appears brighter in the fight against this devastating disease.